Novel Agents in the Treatment of Lung Cancer
First Cambridge Conference - October 2003
This international educational forum of leaders in research and clinical oncology was directed by Dr. Thomas Lynch, Chief, Hematology/Oncology, Massachusetts General Hospital.
The educational objectives were to: review important aspects of lung cancer biology as they pertain to novel treatments; discuss the rationale for identifying a target as therapeutically important; appreciate the role of molecularly targeted agents in the current treatment of advanced lung cancer; assess the ongoing trials using these agents and the impact that such studies may have on future opportunities for patient care. The program was supported by educational grants from industry.
The conference proceedings were published as a peer-reviewed CME supplement to Clinical Cancer Research Clinical Cancer Research. Vol 10. No 12 (Part 2). June 1 2004.
Journal Website
(subscription may be required to access full journal supplement)
